Precigen, Inc

PGEN · United States

Share price · PGEN

$4.27-2.48 (-36.74%) 3M

close as of 2026-11-18 · 24h delayed · vol 4.3M (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PGEN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 5 Nov 2026-16.5%
  2. 2 Nov 2026-25.9%
  3. 29 Oct 2026+9.2%
  4. 16 Oct 2026-11.3%
  5. 5 Oct 2026-9.4%
  6. 31 Jul 2026+5.6%
  7. 11 Jun 2026+16.5%
  8. 14 May 2026+10.8%
  9. 31 Mar 2026+19.1%
  10. 30 Mar 2026-11.4%

Share of unusual movement by asset

For each asset, the share of PGEN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zopapogene imadenovec (Papzimeos)
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—28%
Other company news (earnings, financing, releases naming no asset)—19%
Sessions with no dated event—53%

Assets

(3 total)
3Total Assets
1Approved
0Phase 3 / Filed
2Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
HPV6/HPV11 antigens (immunotherapy)Gene therapy / editing
Recurrent Respiratory Papillomatosis
Phase 2
HPV-16/18 E6/E7 antigensGene therapy / editing
Oropharyngeal Cancer
HPV-Associated Oropharyngeal Cancer
Phase 1
CD33Cell therapy
Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
January 2029 (1)
Zopapogene imadenovec · PapzimeosPhase 3Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis, Papillomavirus Infections
Est. primary completion 2029-01 · NCT07901738 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 August 2025FDA action dateZopapogene imadenovecPDUFA target action date set for August 27, 2025
US, FDA · Source ↗
15 August 2025ApprovalZopapogene imadenovecFDA full approval of PAPZIMEOS for adult RRP
US, FDA · Source ↗
25 February 2025Filing acceptedZopapogene imadenovecFDA accepts BLA for PRGN-2012
US, FDA · Source ↗
25 February 2025Priority reviewZopapogene imadenovecFDA grants priority review to PRGN-2012 BLA
US, FDA · Source ↗
December 2024Filing submittedZopapogene imadenovecRolling BLA submission completed
US, FDA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$74M$6.6M$15M+ $31M short-term inv.—$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$55M$7.3M$16M+ $22M short-term inv.—-$18M operating cash flowreport ↗
2026-Q1$23M$5.6M$7.5M+ $49M short-term inv.$7.9M-$44M operating cash flowreport ↗
2025-Q3——$14M+ $107M short-term inv.$146M-$29M operating cash flowreport ↗
2025-Q2——$14M+ $46M short-term inv.$27M-$19M operating cash flowreport ↗
2025-Q1$1.3M$10M$6.1M+ $74M short-term inv.$54M-$16M operating cash flowreport ↗
2024-Q3——$25M+ $3.9M short-term inv.$24M-$23M operating cash flowreport ↗
2024-Q2——$9.6M+ $10M short-term inv.$59M-$23M operating cash flowreport ↗
2024-Q1——$18M+ $27M short-term inv.$24M-$14M operating cash flowreport ↗
2023-Q3——$10M+ $64M short-term inv.$20M-$17M operating cash flowreport ↗
2023-Q2$1.8M—$17M+ $72M short-term inv.$20M-$16M operating cash flowreport ↗
2023-Q1$1.9M—$24M+ $94M short-term inv.$23M-$18M operating cash flowreport ↗
2022-Q3$17M—$92M+ $62M short-term inv.—-$24M operating cash flowreport ↗
2022-Q2$2.9M—$50M+ $71M short-term inv.$18M-$7.0M operating cash flowreport ↗
2022-Q1$32M—$41M+ $72M short-term inv.$19M-$19M operating cash flowreport ↗
2021-Q3$22M—$42M+ $73M short-term inv.$30M-$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$9.7M$41M$30M+ $68M short-term inv.$63M-$88M operating cash flowreport ↗

Precigen reported full-year 2025 total revenues of $9.68M, up 146.3% YoY, with PAPZIMEOS contributing $3.4M in net product revenue in the fourth quarter. R&D expense was $41.33M, down 22.1% YoY. Cash and equivalents totaled $30.23M, while cash, cash equivalents, and investments reached $100.4M as of December 31, 2025. The company reported a net loss of $250.64M and a quarterly net burn of $250.64M.

The company transitioned to commercial stage after FDA approval of PAPZIMEOS in August 2025, secured a permanent J-code effective April 1, 2026, and has a Marketing Authorization Application for PAPZIMEOS under EMA review. An open-label redosing study was initiated, and PRGN-2009 Phase 2 trials are ongoing. Management expects current cash plus anticipated PAPZIMEOS sales to fund operations to cash flow break-even by the end of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.9M$53M$30M+ $68M short-term inv.$32M-$68M operating cash flowreport ↗
2023-FY$6.2M$49M$7.8M+ $55M short-term inv.$24M-$67M operating cash flowreport ↗
2022-FY$27M—$49M+ $51M short-term inv.—-$65M operating cash flowreport ↗
2021-FY$104M—$43M+ $72M short-term inv.$23M-$56M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($25K), 40 sales ($36.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise10,744$4.72$51KForm 4
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise42,918$2.33$100KForm 4
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise2$0.96$2Form 4
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise1$1.21$1Form 4
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise (derivative)10,744——Form 4
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise (derivative)42,918——Form 4
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise (derivative)2——Form 4
2026-09-23Thomasian Harry Jr. · Chief Financial OfficerOption exercise (derivative)1——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 205 reporting institutions held 133.6M shares ($511.5M, 37.3% of shares outstanding).

#InstitutionSharesValue
1Patient Capital Management, LLC17,817,387$69.0M
2BlackRock, Inc.15,223,191$58.9M
3STATE STREET CORP10,890,124$42.1M
4VANGUARD CAPITAL MANAGEMENT LLC7,148,996$27.7M
5Diametric Capital, LP6,801,788$26.3M
6Point72 Asset Management, L.P.6,644,361$25.7M
7TANG CAPITAL MANAGEMENT LLC6,417,500$24.8M
8GEODE CAPITAL MANAGEMENT, LLC4,613,429$17.9M
9Occam Crest Management LP4,269,051$16.5M
10IRIDIAN ASSET MANAGEMENT LLC/CT3,592,730$13.9M
11Boxer Capital Management, LLC3,500,000$13.5M
12GOLDMAN SACHS GROUP INC3,350,477$13.0M
13CITADEL ADVISORS LLC2,702,383$10.5M
14FRANKLIN RESOURCES INC2,633,780$10.2M
15MORGAN STANLEY2,414,322$9.3M